JNJNYSEhealth care

Johnson & Johnson

$257.77上涨+0.79 (+0.31%)

研究复核截至: 2026年7月12日上午12:00 [UTC]

研究概览

Johnson & Johnson operates in Pharmaceuticals within the health care sector. This profile tracks its company-specific earnings drivers, valuation conditions, and primary-source risks.

開盤: 257.95
最高: 259.51
最低: 256.15
市值: 6205.08億
本益比: 29.87
52 週高點: --
股息: 2.090%
季度股利金額: --

近 3 个月价格

這裡展示近 3 個月價格走勢，幫助使用者先理解短期結構，再決定是否進入完整研究工作台。

投资论点

基础情景: Growth from newer and expanding oncology, immunology, and neuroscience medicines can offset erosion in mature products. The base case remains conditional on talc litigation staying manageable.
多头情景: Growth from newer and expanding oncology, immunology, and neuroscience medicines can offset erosion in mature products. Higher procedure volumes and adoption of newer cardiovascular, surgery, orthopaedics, and vision technologies can support MedTech growth. Regulatory approvals, label expansions, and clinical readouts across medicine and MedTech can create additional durable revenue streams.
空头情景: Pending talc claims create uncertain legal costs, potential judgments, and reputational exposure that may persist despite defense and resolution efforts. Biosimilar or generic competition, government price negotiations, and payer pressure can reduce sales and margins for key medicines. Pipeline assets and medical devices may fail trials, face approval delays, encounter safety findings, or fall short of commercial adoption expectations.

关键催化剂

Innovative Medicine portfolio
Growth from newer and expanding oncology, immunology, and neuroscience medicines can offset erosion in mature products.
MedTech procedure growth
Higher procedure volumes and adoption of newer cardiovascular, surgery, orthopaedics, and vision technologies can support MedTech growth.
Pipeline and indication expansion
Regulatory approvals, label expansions, and clinical readouts across medicine and MedTech can create additional durable revenue streams.

主要风险

Talc litigation
Pending talc claims create uncertain legal costs, potential judgments, and reputational exposure that may persist despite defense and resolution efforts.
Exclusivity and pricing pressure
Biosimilar or generic competition, government price negotiations, and payer pressure can reduce sales and margins for key medicines.
Clinical and regulatory execution
Pipeline assets and medical devices may fail trials, face approval delays, encounter safety findings, or fall short of commercial adoption expectations.

估值解读

Valuation should separate the growth and patent profiles of Innovative Medicine from the procedure-driven economics of MedTech.
A durability premium depends on pipeline replacement of mature products and should be tempered by litigation and regulatory uncertainty.